⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.
BCAX — Bicara Therapeutics Inc.
Last scan (Nov. 5, 2026): price $8.89, RSI 22.41, relative volume 0.52x, MACD ⚪ No, score 55.86.
It's trading below its 200-day average, with an RSI of 22.41 in oversold territory — technically weak, though that can also signal the pessimism is already priced in. Neither the MACD nor a range breakout gives a technical entry signal right now. Relative volume of 0.52x is below normal — little interest today. The analysts' average target price implies +281.6% upside — one of the score's strongest signals.
Price chart
BCAX
Price: $8.89 · RSI (14): 34.94 · Rel. volume: 0.42x · Breakout: No
- Current price: ($8.89) — solid white line — the latest available closing price.
- Target price: ($33.92) — dashed green line — average 12-month target price from analysts covering the stock.
- Quarter low: ($7.87) — dotted orange line — the lowest price over the last ~3 months, as a recent support reference.
You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.
What analysts say
BCAX
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human…
- Buy 13
- Hold 0
- Sell 1
Average target price: $33.92 (+281.5% vs. current price) · range $8.0 – $45.0
Healthy Moderate Attention No data
Total market value of the company (price × shares outstanding).
?
P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.
Not enough data to calculate it (no recent earnings or data unavailable).
?
P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.
Same as P/E, using estimated future earnings.
?
PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.
Not enough data (requires future growth estimates).
?
Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.
Low leverage: conservative balance sheet, less risk if interest rates rise.
?
Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.
Low margin: the business has little cushion if costs rise.
?
Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.
Doesn't pay dividends: reinvests earnings into growth instead of distributing them.
?
Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).
Less volatile than the overall market (S&P 500 = 1.0).
General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.
💰 Financial Statements (last 3 quarters)
💰 Financial Statements (last 3 quarters)
What this chart shows
- Japanese candlesticks: green when the period's close is higher than its open, red when it's lower.
- Volume: bars colored the same as the candle for that period.
- RSI (14): bottom line with reference levels at 70 (overbought) and 30 (oversold) — the same indicator the daily scanner uses.
- Dotted line on top: the high of the last 20 periods, the same reference the scanner uses to detect breakouts.
Third-party market data, for informational purposes. Not investment advice — read the disclaimer.